BGI
DRUG

B Group Inc’s Bright Minds Biosciences DRUG Stock Holding History

B Group Inc’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.93M Buy
+67,500
New +$5.43M 3.65% 11

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

B Group Inc's DRUG Position: Q1 2026 in Review

B Group Inc opened a new position in Bright Minds Biosciences (DRUG) in Q1 2026: 67,500 shares worth $4.93M. The stake represents 3.65% of the portfolio and ranks #11 among its holdings.

94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • B Group Inc held 67,500 shares of Bright Minds Biosciences worth $4.93M as of Q1 2026.
  • Bright Minds Biosciences was a new B Group Inc position in Q1 2026.
  • Bright Minds Biosciences made up 3.65% of B Group Inc's portfolio in Q1 2026, its #11 holding.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on B Group Inc's 13F filing for Q1 2026, filed 15 May 2026.